The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
Kenji NozakiDai MaruyamaAkiko Miyagi MaeshimaKinuko TajimaJun ItamiTakafumi ShichijoSayako YudaTomotaka SuzukiKosuke ToyodaNobuhiko YamauchiShinichi MakitaSuguru FukuharaWataru MunakataYukio KobayashiHirokazu TaniguchiKoji IzutsuKensei TobinaiPublished in: European journal of haematology (2020)
Our data support the recommendation of LRT for HT lesion treatment following rituximab-containing chemotherapy in select patients with localised HT, as a rational treatment approach with potentially limited toxicity.